Silence Therapeutics plc (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Analysts

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $40.67.

Several brokerages have recently weighed in on SLN. Morgan Stanley reduced their price target on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. BMO Capital Markets lowered their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group cut their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research report on Tuesday, March 4th.

Silence Therapeutics Trading Up 8.9 %

Shares of SLN stock traded up $0.27 during trading on Friday, reaching $3.32. 279,780 shares of the company's stock traded hands, compared to its average volume of 294,913. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $24.38. The company has a market capitalization of $99.37 million, a P/E ratio of -2.11 and a beta of 1.25. The firm's 50-day moving average is $3.65 and its 200 day moving average is $7.81.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently bought and sold shares of the stock. Redmile Group LLC raised its holdings in shares of Silence Therapeutics by 26.3% during the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock valued at $16,507,000 after buying an additional 500,000 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Silence Therapeutics by 424.8% in the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock worth $7,222,000 after acquiring an additional 849,676 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Silence Therapeutics by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock valued at $4,356,000 after purchasing an additional 165,300 shares in the last quarter. Cantor Fitzgerald L. P. grew its holdings in shares of Silence Therapeutics by 61.5% during the 4th quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company's stock valued at $3,713,000 after purchasing an additional 205,534 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Silence Therapeutics by 48,165.6% in the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock worth $3,434,000 after purchasing an additional 498,032 shares during the period. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.